TIL will be grown and expanded for this trial accordin g to standard operating procedures submitted in the IND. After a sufficient yield of TIL (5x107cells) is expanded and PBMCs a re available, immunogenic neoantigens will be i dentified by high throughput immunologic s creening using long peptides and tandem minigenes covering a ll mutated epitopes to identify the exact mutations recognized by autologous T cells. For vacci ne preparation, patients will u ndergo apheresis and DCs will be produced and cryopreserved for va ccine preparation. Peptides (1 5-25mers with the mutation at positions 13) or minimal epitopes (9 -10mers) will be synthesize d and pulsed on autologous antigen presenting cells (DC). T he antigen pulsed DC will then b e matured using a TLR mix. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 17Patients will receive peptide-load ed mature dendritic cells intr avenously and subcutaneously at biweekly intervals for 4 cycles. Immunologic tests will be perform ed as described in Section 5.5. 3.1.2 Treatment Phase The protocol will consist of two cohorts: cohor t 1, patients wi th melanoma and cohort 2, patients with epithelial cancer.The study will utilize an optimal design where initially 21 eva luable patients w ill be enrolled to each cohort. If 0 or 1 of the 21 patie nts in a given cohort exp eriences a clinical response, then no further patients will be enrolled; if 2 or m ore of the first 21 evaluable patients enrolled have a clinical response, then accrual will continue until a total of 41 evaluable patients have been enrolled to that cohort.Patients will receive no other exp erimental agents while on thi s protocol. All patients will receive one course of treatment (4 vaccination cycles). The sta rt date of the cour se will be the start date of the first vaccina tion; the end date will be the da y of the first post-treatment evaluation (week 8 if the patie nt receives all 4 cycles). Enrollment will be staggered within each cohort with three weeks between start dates for the first three patients to allow for a 3-week interval for safety assess ment before the next enrolled patient is scheduled to receive their first dose of the DC vaccine. 3.1.3 Protocol Stopping Rules New subject enrollment to the protocol will be temporarily halted if any of the following conditions are met, and discussi ons will be had with the FDA or NIH IRB regarding protocol revisions if applicable: xIf one or more treatment-relat ed death occurs due to vaccination, we will promptly discuss this with the NCI IRB and the FDA. xTwo or more patients develop a grad e 3 or greater toxicity at an y point in the study not attributable to disease progre ssion (or circumstances unrelated to the study). oThe following grade 3 reactions c ommonly associated with immuni zation will not be included in this protocol stopping rule: Pruritus/itching: inte nse or widespread and interfering with AD L lasting <72 hours Fatigue: severe fatigue interfering with ADL lasting < 72 hours Fever: > 40.0°C for < 24 hours Local lymphadenopathy lasting < 1 week xIf one of the first three patients (or 2 of the first 6 patients, or 3 of the first 9 patients, or 4 of the first 12 patient s) develop grade 3 autoimmunity, that ca nnot be resolved to less than or equal to a gra de 2 autoimmune toxicity within 10 days, or any grade 4 or greater autoimmune toxicity. DRUG ADMINISTRATION Patients will receive peptide pulsed dendritic cell vaccines on days 0, 14 (± 5 days), 28 (± 5 days), and 42 (± 5 days). The vaccin e will be administered as both an intravenous (IV) infusion Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 18and a subcutaneous (SQ) injecti on. The total dose will be divided eq ually between IV and SQ containing 1.0x107to 8.0x107cells per cycle depending upon the manufacturing yield. The patient’s dendritic cell products will be delivered to the Pa tient Care Unit by a staff member from the NCI SB. Prior to infusi on, the cell product identity la bels on the syringe and cell infusion bag will be double-checke d by two authorized staff (MD or RN), an iden tification of the product and documentation of adminis tration are entered in the patient’s chart, as is done for blood banking protocols. xCells for SQ injecti on will be administered f irst, followed by cells for IV infusion. xCells for SQ injectio n will be administe red in a total of 1.0 mL (0.5x107to 4.0x107cells) into the deep subcutaneous tissu e of a proximal ex tremity. Inje ctions will preferentially be administered in the anterior thigh.